Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 121.67 — trading above book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -3,098.5%
Elicio Therapeutics, Inc. (ELTX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $199 million . Key value metrics: P/B ratio 121.67, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Elicio Therapeutics, Inc. — Fundamental Analysis Summary
On financial health, ELTX shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -3,098.5% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 6.11.
StockPik's composite Value Score for ELTX is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ELTX reports a solid gross margin of 58.7% (sector average: 33.5%) and a negative operating margin of -1,919.2%.
ELTX shows earnings growing at 24%.